Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease.
暂无分享,去创建一个
[1] J. Loscalzo,et al. Role of oxidative stress and nitric oxide in atherothrombosis. , 2008, Frontiers in bioscience : a journal and virtual library.
[2] S. Abman,et al. BAY 41-2272, a Direct Activator of Soluble Guanylate Cyclase, Reduces Right Ventricular Hypertrophy and Prevents Pulmonary Vascular Remodeling during Chronic Hypoxia in Neonatal Rats , 2006, Neonatology.
[3] A. Friebe,et al. Inhibition of Phosphodiesterase Type 5 by the Activator of Nitric Oxide–Sensitive Guanylyl Cyclase BAY 41-2272 , 2004, Circulation.
[4] J. Wharton,et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. , 2005, American journal of respiratory and critical care medicine.
[5] S. Abman,et al. Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. , 2005, American journal of physiology. Lung cellular and molecular physiology.
[6] O. V. Evgenov,et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential , 2006, Nature Reviews Drug Discovery.
[7] M. Humbert,et al. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: critical role for serotonin-induced smooth muscle hyperplasia. , 2006, Circulation.
[8] A. Mebazaa,et al. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure. , 2013, European Heart Journal.
[9] S. Kuo,et al. Inhibition of extracellular Ca(2+) entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils. , 2001, Biochemical pharmacology.
[10] Ralph D'Agostino,et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. , 2004, The New England journal of medicine.
[11] Ka Bian,et al. Discovery of the nitric oxide signaling pathway and targets for drug development. , 2009, Frontiers in bioscience.
[12] P. Sehgal,et al. Dependence of Golgi apparatus integrity on nitric oxide in vascular cells: implications in pulmonary arterial hypertension. , 2011, American journal of physiology. Heart and circulatory physiology.
[13] W. Seeger,et al. Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury. , 2009, American journal of physiology. Lung cellular and molecular physiology.
[14] J. Stasch,et al. Discovery of Riociguat (BAY 63‐2521): A Potent, Oral Stimulator of Soluble Guanylate Cyclase for the Treatment of Pulmonary Hypertension , 2009, ChemMedChem.
[15] F. Murad,et al. Nitric Oxide and Cyclic GMP in Cell Signaling and Drug Development , 2006 .
[16] T. Noll,et al. Stimulation of cGMP signalling protects coronary endothelium against reperfusion-induced intercellular gap formation. , 2009, Cardiovascular research.
[17] J. Stasch,et al. Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart , 2009, Hypertension Research.
[18] R. Arena,et al. Long-term use of sildenafil in the therapeutic management of heart failure. , 2007, Journal of the American College of Cardiology.
[19] W. Seeger,et al. Activation of Soluble Guanylate Cyclase Reverses Experimental Pulmonary Hypertension and Vascular Remodeling , 2006, Circulation.
[20] W. Linz,et al. Biochemistry and Pharmacology of Novel Anthranilic Acid Derivatives Activating Heme-Oxidized Soluble Guanylyl Cyclase , 2006, Molecular Pharmacology.
[21] M. Karck,et al. Pharmacological Activation of Soluble Guanylate Cyclase Protects the Heart Against Ischemic Injury , 2009, Circulation.
[22] J. Annichino-Bizzacchi,et al. EFFECT OF BAY 41‐2272 IN THE PULMONARY HYPERTENSION INDUCED BY HEPARIN–PROTAMINE COMPLEX IN ANAESTHETIZED DOGS , 2007, Clinical and experimental pharmacology & physiology.
[23] J. Stasch,et al. Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure , 2007, Hypertension.
[24] A. Friebe,et al. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. , 1998, Molecular pharmacology.
[25] Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. , 1998, The European respiratory journal.
[26] E. Antunes,et al. Protective Effects of BAY 41-2272 (sGC Stimulator) on Hypertension, Heart, and Cardiomyocyte Hypertrophy Induced by Chronic L-NAME Treatment in Rats , 2006, Journal of cardiovascular pharmacology.
[27] W. Seeger,et al. Inhalative application of soluble guanylyl cyclase stimulator BAY 41–8543 for treatement of pulmonary arterial hypertension , 2010 .
[28] W. Haefeli,et al. Significant Pharmacokinetic and Pharmacodynamic Interaction of Warfarin With the NO‐Independent sGC Activator HMR1766 , 2007, Journal of clinical pharmacology.
[29] S. Eddahibi,et al. Lessons from oncology to understand and treat pulmonary hypertension , 2007, International journal of clinical practice. Supplement.
[30] G. Schultz,et al. Sensitizing soluble guanylyl cyclase to become a highly CO‐sensitive enzyme. , 1996, The EMBO journal.
[31] J. Stasch,et al. Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. , 2003, European journal of pharmacology.
[32] Csaba Szabó,et al. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics , 2007, Nature Reviews Drug Discovery.
[33] C. Szabó,et al. Nitrosative stress and pharmacological modulation of heart failure. , 2005, Trends in pharmacological sciences.
[34] R. Busse,et al. Effect of YC‐1, an NO‐independent, superoxide‐sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators , 1997, British journal of pharmacology.
[35] J. Stasch,et al. Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[36] K. Amann,et al. Blood Pressure-Independent Effect of Long-Term Treatment with the Soluble Heme-Independent Guanylyl Cyclase Activator HMR1766 on Progression in a Model of Noninflammatory Chronic Renal Damage , 2007, Kidney and Blood Pressure Research.
[37] W. Durante,et al. YC-1, a benzyl indazole derivative, stimulates vascular cGMP and inhibits neointima formation. , 2000, Biochemical and biophysical research communications.
[38] J. Stasch,et al. cGMP: Generators, Effectors and Therapeutic Implications , 2009 .
[39] A. Hatzelmann,et al. Inhibition of TGF-beta induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase. , 2007, European journal of pharmacology.
[40] S. N. Murthy,et al. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. , 2011, American journal of physiology. Heart and circulatory physiology.
[41] F. Martinez,et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. , 2009, Journal of the American College of Cardiology.
[42] S. Saad,et al. Increased adhesive properties of neutrophils in sickle cell disease may be reversed by pharmacological nitric oxide donation , 2008, Haematologica.
[43] J. Stasch,et al. Pharmacological actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vitro studies , 2002, British journal of pharmacology.
[44] S. Kuo,et al. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. , 1997, European journal of pharmacology.
[45] J. Stasch,et al. Cardiovascular actions of a novel NO‐independent guanylyl cyclase stimulator, BAY 41‐8543: in vivo studies , 2002, British journal of pharmacology.
[46] O. V. Evgenov,et al. Soluble Guanylate Cyclase Activator Reverses Acute Pulmonary Hypertension and Augments the Pulmonary Vasodilator Response to Inhaled Nitric Oxide in Awake Lambs , 2004, Circulation.
[47] O. Eickelberg,et al. From arginine methylation to ADMA: A novel mechanism with therapeutic potential in chronic lung diseases , 2009, BMC pulmonary medicine.
[48] L. Ignarro. Nitric oxide : biology and pathobiology , 2000 .
[49] W. Seeger,et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension , 2008, European Respiratory Journal.
[50] N. Weissmann,et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension , 2009, European Respiratory Journal.
[51] R. Gerszten,et al. Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007, Circulation.
[52] J. Horowitz,et al. Impaired tissue responsiveness to organic nitrates and nitric oxide: a new therapeutic frontier? , 2007, Pharmacology & therapeutics.
[53] D. Koesling,et al. Inhibition of Deactivation of NO-sensitive Guanylyl Cyclase Accounts for the Sensitizing Effect of YC-1* , 2002, The Journal of Biological Chemistry.
[54] S. N. Murthy,et al. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide. , 2010, American journal of physiology. Heart and circulatory physiology.
[55] D. Kaye,et al. Impaired l-Arginine Transport and Endothelial Function in Hypertensive and Genetically Predisposed Normotensive Subjects , 2004, Circulation.
[56] J. Stasch,et al. BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats. , 2010, European journal of pharmacology.
[57] F. Grimminger,et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study , 2010, European Respiratory Journal.
[58] J. Stasch,et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. , 2006, The Journal of clinical investigation.
[59] M. Paul,et al. Acute blood pressure effects of YC‐1‐induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats , 2000, British journal of pharmacology.
[60] Chin‐Chung Wu,et al. Potentiation of tumor necrosis factor-alpha expression by YC-1 in alveolar macrophages through a cyclic GMP-independent pathway. , 2003, Biochemical pharmacology.
[61] J. Tamargo,et al. Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure. , 2010, Current opinion in investigational drugs.
[62] W. Seeger,et al. Inhalative Application Of Soluble Guanylyl Cyclase Stimulator BAY 41-8543 For Treatement Of Pulmonary Arterial Hypertension , 2010, ATS 2010.
[63] A. Chockalingam,et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. , 2005, International journal of cardiology.
[64] S. Kuo,et al. YC-1, a novel activator of platelet guanylate cyclase. , 1994, Blood.
[65] M. Schwaiblmair,et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. , 2004, Chest.
[66] R. Girgis. Emerging drugs for pulmonary hypertension , 2010, Expert opinion on emerging drugs.
[67] Jesse D. Roberts,et al. Inhaled NO as a therapeutic agent. , 2007, Cardiovascular research.
[68] Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[69] J. West,et al. YC-1-mediated vascular protection through inhibition of smooth muscle cell proliferation and platelet function. , 2002, Biochemical and biophysical research communications.
[70] D. Badesch,et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. , 1999, American journal of respiratory and critical care medicine.
[71] M. Gheorghiade,et al. Role of guanylate cyclase modulators in decompensated heart failure , 2009, Heart Failure Reviews.
[72] J. Stasch,et al. NO‐ and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle , 2002, British journal of pharmacology.
[73] Zhihong Yang,et al. Recent advances in understanding endothelial dysfunction in atherosclerosis. , 2006, Clinical medicine & research.
[74] HaraldLapp,et al. Cinaciguat (BAY 58–2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure , 2009 .
[75] I. Charles,et al. Synthesis and biological evaluation of novel pyrazoles and indazoles as activators of the nitric oxide receptor, soluble guanylate cyclase. , 2001, Journal of medicinal chemistry.
[76] L. Liaudet,et al. Nitric oxide and peroxynitrite in health and disease. , 2007, Physiological reviews.
[77] Chieh-Hsi Wu,et al. The inhibitory mechanism of YC-1, a benzyl indazole, on smooth muscle cell proliferation: an in vitro and in vivo study. , 2004, Journal of pharmacological sciences.
[78] J. Hansen,et al. Soluble Guanylate Cyclase Agonists Inhibit Expression and Procoagulant Activity of Tissue Factor , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[79] M. Humbert,et al. Pulmonary arterial hypertension , 2013, Orphanet Journal of Rare Diseases.
[80] D. Kass,et al. Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics. , 2009, Pharmacology & therapeutics.
[81] S. Moncada,et al. Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[82] D. Madge,et al. A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats , 2004, International Journal of Impotence Research.
[83] T. Münzel,et al. Explaining the phenomenon of nitrate tolerance. , 2005, Circulation research.
[84] J. Stasch,et al. NO-independent stimulators of soluble guanylate cyclase. , 2001, Bioorganic & medicinal chemistry letters.
[85] M. Claudino,et al. Long‐term oral treatment with BAY 41‐2272 ameliorates impaired corpus cavernosum relaxations in a nitric oxide‐deficient rat model , 2011, BJU international.
[86] S. Moncada,et al. Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272. , 2003, Vascular pharmacology.
[87] B. Groves,et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.
[88] R. Arena,et al. Pulmonary hypertension with left-sided heart disease , 2010, Nature Reviews Cardiology.
[89] D. Moertl,et al. Pulmonary hypertension in chronic heart failure , 2009, International journal of clinical practice. Supplement.
[90] C. Wanner,et al. Effects of the soluble guanylyl cyclase activator, YC‐1, on vascular tone, cyclic GMP levels and phosphodiesterase activity , 1999, British journal of pharmacology.
[91] J. Stasch,et al. NO- and haem-independent soluble guanylate cyclase activators. , 2009, Handbook of experimental pharmacology.
[92] L. Ghiadoni,et al. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. , 1996, Circulation.
[93] M. Gladwin. Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome. , 2006, The Journal of clinical investigation.
[94] J. Stasch,et al. BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase. , 2002, Biochemical and biophysical research communications.
[95] J. Stasch,et al. Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension , 2009, BMC Pharmacology.
[96] C. Bauters,et al. [Pathophysiology of coronary artery disease]. , 2008, La Revue du praticien.
[97] J. Garthwaite,et al. Probing the presence of the ligand‐binding haem in cellular nitric oxide receptors , 2008, British journal of pharmacology.
[98] J. Dinges,et al. A concise synthesis of ortho-substituted aryl-acrylamides: potent activators of soluble guanylyl cyclase , 2003 .
[99] F. Murad,et al. Human recombinant soluble guanylyl cyclase: expression, purification, and regulation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[100] J. Stasch,et al. NO-independent, haem-dependent soluble guanylate cyclase stimulators. , 2009, Handbook of experimental pharmacology.
[101] J. Stasch,et al. Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure , 2003, Circulation.
[102] L. Goldraich,et al. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial. , 2008, Journal of cardiac failure.
[103] Yin C Lin,et al. Modulation of human monocyte-derived dendritic cells maturation by a soluble guanylate cyclase activator, YC-1, in a cyclic nucleotide independent manner. , 2007, International immunopharmacology.
[104] J. Stasch,et al. Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition. , 2004, Circulation.
[105] G. Wensing,et al. Riociguat (BAY 63–2521) and Warfarin: A Pharmacodynamic and Pharmacokinetic Interaction Study , 2011, Journal of clinical pharmacology.
[106] J. Stasch,et al. Soluble Guanylate Cyclase: Allosteric Activation and Redox Regulation , 2010 .
[107] M. Nakane,et al. A-350619: a novel activator of soluble guanylyl cyclase. , 2003, Life sciences.
[108] P. Ferdinandy,et al. Cyclic GMP and protein kinase‐G in myocardial ischaemia‐reperfusion: opportunities and obstacles for survival signaling , 2007, British journal of pharmacology.
[109] N. Weissmann,et al. Cellular and molecular basis of pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.
[110] J. Stasch,et al. Soluble Guanylate Cyclase Stimulation on Cardiovascular Remodeling in Angiotensin II–Induced Hypertensive Rats , 2006, Hypertension.
[111] A Giaid,et al. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. , 1995, The New England journal of medicine.
[112] H. Ghofrani,et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. , 2009, Journal of the American College of Cardiology.
[113] J. Downey,et al. BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts. , 2009, European heart journal.
[114] J. Stasch,et al. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation‐induced degradation , 2009, British journal of pharmacology.
[115] D. Hess,et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. , 2007, American journal of respiratory and critical care medicine.
[116] G. Schultz,et al. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. , 1998, Molecular pharmacology.
[117] W. Seeger,et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[118] D. Kass,et al. Sustained Soluble Guanylate Cyclase Stimulation Offsets Nitric-Oxide Synthase Inhibition to Restore Acute Cardiac Modulation by Sildenafil , 2008, Journal of Pharmacology and Experimental Therapeutics.
[119] J. Stasch,et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models , 2010, Journal of hypertension.
[120] H. Ghofrani,et al. Riociguat For Chronic Thromboembolic Pulmonary Hypertension And Pulmonary Arterial Hypertension: First Long-term Extension Data From A Phase II Study , 2010, ATS 2010.
[121] L. Storme,et al. Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. , 2005, American journal of physiology. Lung cellular and molecular physiology.
[122] J. Bauersachs,et al. Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. , 2010, Pharmacological research.
[123] J. Stasch,et al. Structure of Cinaciguat (BAY 58–2667) Bound to Nostoc H-NOX Domain Reveals Insights into Heme-mimetic Activation of the Soluble Guanylyl Cyclase* , 2010, The Journal of Biological Chemistry.
[124] D. Kass,et al. Phosphodiesterase regulation of nitric oxide signaling. , 2007, Cardiovascular research.
[125] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.
[126] R. Gerzer,et al. NO-independent regulatory site on soluble guanylate cyclase , 2001, Nature.
[127] J. Tanus-Santos,et al. Dose-dependent beneficial hemodynamic effects of BAY 41-2272 in a canine model of acute pulmonary thromboembolism. , 2008, European journal of pharmacology.
[128] J. Stasch,et al. Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure , 2009, BMC Pharmacology.
[129] M. Nakane,et al. Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator. , 2006, Journal of pharmacological sciences.
[130] G. Wensing,et al. Single‐Dose Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of the Soluble Guanylate Cyclase Stimulator BAY 63‐2521: An Ascending‐Dose Study in Healthy Male Volunteers , 2008, Journal of clinical pharmacology.